About the Project
In this project, the PhD candidate will synthesise a new generation of our initial compounds aimed at improving their dose response by improving their ability to use LAT-1 as the uptake mechanism. The candidate will also screen these compounds and their controls against various cancerous and healthy cells lines to identify potential therapeutic application of the molecules.
The candidate is expected to be a synthetic organic chemist with a strong knowledge of biochemistry and willing to learn practical cellular biology.
Eligibility and How to Apply:
Please note eligibility requirement:
• Academic excellence of the proposed student i.e. 2:1 (or equivalent GPA from non-UK universities [preference for 1st class honours]); or a Masters (preference for Merit or above); or APEL evidence of substantial practitioner achievement.
• Appropriate IELTS score, if required.
• Applicants cannot apply for this funding if currently engaged in Doctoral study at Northumbria or elsewhere.
For further details of how to apply, entry requirements and the application form, see
Please note: Applications should include a covering letter that includes a short summary (500 words max.) of a relevant piece of research that you have previously completed and the reasons you consider yourself suited to the project. Applications that do not include the advert reference (e.g. SF20/…) will not be considered.
Deadline for applications: 1st July for October start, or 1st December for March start
Start Date: October or March
Northumbria University takes pride in, and values, the quality and diversity of our staff. We welcome applications from all members of the community. The University holds an Athena SWAN Bronze award in recognition of our commitment to improving employment practices for the advancement of gender equality.
Please direct enquiries to Dr David Tetard ([Email Address Removed])
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.